Patricia Ares-Romero, MD
Psychiatry · Hanford, CANPI 1902823719
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $344,404 of the $507,884 with a category attached, or 67.8%. 21 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 32.3% of the total. 2025 is the largest year on record at $176,557, 2.9 times the $61,736 reported in 2019. Among psychiatry clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 709 payments — averaging $716.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$164K
- Neurocrine Biosciences, Inc.$138K
- Johnson & Johnson$61K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$54K
- Alkermes, Inc.$42K
- Otsuka America Pharmaceutical, Inc.$38K
- plus $11K from 15 others
What the payments were for
- Consulting fees$83,14316%
- Speaking & faculty fees$344,40468%
- Travel & lodging$59,65712%
- Food & beverage$20,6624%
- Education$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 168 | $164,121 |
| Neurocrine Biosciences, Inc. | 168 | $137,653 |
| Johnson & Johnson(2 entities) | 114 | $61,040 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 67 | $53,761 |
| Alkermes, Inc. | 68 | $42,302 |
| Otsuka America Pharmaceutical, Inc. | 53 | $38,310 |
| Indivior Inc. | 21 | $4,428 |
| Sandoz | 1 | $3,971 |
| Pear Therapeutics (US), Inc. | 5 | $497 |
| Teva Pharmaceuticals USA, Inc. | 10 | $283 |
| Neuronetics, Inc. | 3 | $274 |
| AbbVie | 6 | $210 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $183 |
| Livanova USA, Inc. | 3 | $177 |
| Boston Scientific | 1 | $156 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $140 |
| Sunovion Pharmaceuticals Inc. | 6 | $124 |
| AstraZeneca | 1 | $89 |
| Lundbeck LLC | 4 | $76 |
| Biogen | 1 | $71 |
| Brainsway USA Inc | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$164,943
- INGREZZA$134,939
- COBENFY$116,408
- SPRAVATO$54,803
- CAPLYTA$52,611
- ARISTADA INITIO$41,236
- ABILIFY MAINTENA$36,767
- RESET-O$4,384
- SUBLOCADE$4,114
- INVEGA SUSTENNA$4,080
- REXULTI$1,582
- LYBALVI$472
- WATCHMAN FLX$156
- VNS - Symmetry$134
- AUSTEDO$123
- REJOYN$122
- NEUROSTAR TMS THERAPY$121
- RISPERDAL$120
- VRAYLAR$113
How this compares
$507,884 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other psychiatry in Hanford
- Bradley WajdaHanford$101K
- Gustavo AlvaOrange$5.8M
- John KooSan Francisco$3M
- Jason KelloggIrvine$2.7M
- Jonathan MeyerSan Diego$2.3M
- Charles Tuan-Tu NguyenIrvine$2.1M
- Manoj WaikarLos Gatos$1.9M
- Gerald MaguireSan Juan Capistraco$1.8M
- Salima BrillmanSunnyvale$1.4M
- Bibi DasStanford$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.